Cordis to present clinical data for Cypher Stent in heart attacks at ACC 2006

By Lisa Kerner

Erie, Pa., March 8 - Cordis Corp., a Johnson & Johnson company, said the Cypher Stent has demonstrated significant benefit in reducing late loss versus the Taxus Stent in eight randomized clinical trials comparing the two stents.

The company will present the data and additional results at the 2006 American College of Cardiology Scientific Session in Atlanta next week that Cordis says will add to the growing body of evidence for the Cypher Stent, according to a news release.

Specifically, clinical investigators will report on the first randomized trial clinical examining the use of the Cypher Sirolimus-eluting Coronary Stent in patients experiencing a heart attack. Investigators will also discuss two head-to-head randomized clinical trials comparing the Cypher Stent and the Taxus Stent in difficult-to-treat patients and in patients experiencing a heart attack.

"ACC 2006 will be an exciting congress for Cordis, with compelling data expected across many frontiers," vice president, worldwide regulatory and clinical affairs, Dennis Donohoe said in the release.

"The breadth of clinical data from Cordis Corp. will provide physicians and patients with new information about coronary artery disease, stroke, heart attacks and adult cell therapy."

Cordis, based in Miami Lakes, Fla., develops and manufactures interventional vascular technology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.